A recent interview with Dr. Seidensticker highlights the findings of the PROKOMB study, which indicates that the majority of prostate cancer biopsies may be unnecessary. The study advocates for using MRI as the first diagnostic step, which could significantly reduce invasive biopsies and associated risks. Key findings reveal that an MRI-informed strategy could prevent 41% of all men and 86% of MRI-negative men from undergoing unnecessary biopsies over three years. This research has influenced recent updates to German prostate cancer guidelines, enhancing evidence-based patient care. Prostate MRI, particularly multiparametric MRI, is positioning itself as a standard diagnostic practice, with an expected increase in procedures and advancements in contrast agents aimed at improving diagnostic accuracy while reducing patient exposure to gadolinium. Bayer is actively working to innovate in this field, addressing barriers such as costs and the need for specialized training, which could facilitate broader adoption of MRI-first pathways in prostate cancer diagnostics. Overall, the MRI-first approach promises to improve outcomes, minimize unnecessary procedures, and lower healthcare costs for prostate cancer patients.
Wed, 22 Oct 2025 06:01:38 GMT | healthcare-in-europe.com